Insider trading allegations stall Sun–Ranbaxy deal


The merger deal that would create India’s largest pharmaceutical company has been stalled by accusations of insider trading of shares in the lead-up to the takeover announcement. The High Court of Andhra Pradesh has halted the transaction between Sun Pharma and Ranbaxy while the allegations are investigated.

The allegations centre on an unusually rapid increase in Ranbaxy’s share price in the week before the deal was announced. Sun Pharma has denied any wrongdoing, saying in a statement that: ‘The matter related to purchase of shares of Ranbaxy Laboratories does not violate insider trading rules.’


Related Content

Sun Pharma snares Ranbaxy in $4bn deal

1 April 2015 Business

news image

Acquisition makes Sun biggest drug firm in India and fifth largest generics producer in the world

Sun set on Ranbaxy rescue

9 April 2014 Business

news image

Acquiring beleaguered firm will create India’s biggest pharmaceutical company

Most Commented

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...